N.E. AFANASYEV¹, N.V. AGRANOVICH², V.A. BATURIN², V.О. AGRANOVICH², S.D. SOCHILOVA³, O.V. SEMENYAK³

 ¹City Clinical Polyclinic No. 5, Stavropol

²Stavropol State Medical University, Stavropol

³City Clinical Hospital No. 3, Stavropol

 Сontact details:

Afanasyev N.E. — PhD (Medicine), therapist, Head of the Unit for Specialized Medical and Sanitary Aid

Address: 15 Zarechniy proyezd, 355026 Stavropol, Russian Federation, tel.: +7-928-813-70-88, e-mail: dvamedika03@yandex.ru

 The study involved 1,402 patients with COVID-19 (moderate severity with community-acquired pneumonia) who received inpatient treatment at the Therapy Department of City Clinical Hospital No. 3 in Stavropol from January 2021 to March 2022. There occurred 20 deaths (1.4%). The article presents an analysis of clinical and laboratory data of these patients. The comparison group included 20 patients who were discharged from the hospital (the inclusion criterion was the same gender and age as that of the deceased). The patients with fatal outcomes were predominantly diagnosed with pneumonia on CT-3, and in 100% of cases, they had various comorbidities. The analysis demonstrates that certain biomarkers, such as leukocytes, lymphocytes, urea, creatinine, CRP, and ferritin, can predict a fatal outcome independently of other factors. This confirms the results of numerous studies aimed at identifying signs of severe COVID-19. Integrating these mortality predictors into clinical practice will allow for the development of more effective patient management strategies and reduce mortality rates.

Key words: COVID-19, fatal outcome, predictors, comorbidity

 REFERENCES

1. Koronavirus v Rossii, svezhaya statistika na segodnya po zabolevshim. 20 aprelya 2026 g. [Coronavirus in Russia, latest statistics for today on cases. April 20, 2026], available at: https://coronavirus-graph.ru/rossiya
2. Vremennyye metodicheskiye rekomendatsii «Profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19). Versiya 13» ot 14 oktyabrya 2021 g. [Interim guidelines «Prevention, diagnosis, and treatment of novel coronavirus infection (COVID-19). Version 13» dated October 14, 2021]
3. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol, 2020, vol. 5 (4), pp. 536–544. DOI: 10.1038/s41564-020-0695-z
4. Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G. et al. International registry «Analysis of the dynamics of comorbid diseases in patients who survived SARS-CoV-2 infection» (ACTIVE SARS-CoV-2): analysis of predictors of adverse outcomes in the acute stage of a new coronavirus infection. Rossiyskiy kardiologicheskiy zhurnal, 2021, no. 26 (4), pp. 116–131 (in Russ.). DOI: 10.15829/1560-4071- 2021-4470
5. Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C. et al. Factors associated with COVID-19-related death using Open SAFELY. Nature, 2020, vol. 584 (7821), pp. 430–436. DOI: 10.1038/s41586-020-2521-4
6. Mann H.B., Whitney D.R. On a test of whether one of two random variables is stochastically larger than the other. Ann. Math. Stat, 1947, no. 18, pp. 50–60.
7. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis, 1987, vol. 40 (5), pp. 373–383. DOI: 10.1016/0021- 9681(87)90171-8
8. Henry B. M., Santos de Oliveira M. H., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID19): a meta-analysis. Clin. Chem. Lab. Med, 2020, vol. 58 (7), pp. 1021–1028. DOI: 10.1515/cclm-2020-0369